Clinical Trial Update: An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating apalutamide (JNJ-56021927) in high-risk prostate cancer patients receiving primary radiation therapy (ATLAS).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Apalutamide (apalutamide)
• JNJ-56021927

Snippet

Sponsor: Aragon Pharmaceuticals, Inc. | Conditions: Prostatic Neoplasms | Phase 3 | Status: ACTIVE_NOT_RECRUITING